Do reimbursement recommendations by the Canadian Agency for Drugs and Technology in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario?
This study is the first to look at this question for orphan drugs which are at the centre of policy attention.
Source: Value in Health - Category: International Medicine & Public Health Authors: Anna-Maria Fontrier, Panos Kanavos Source Type: research
More News: Canada Health | Government | International Medicine & Public Health | Rare Diseases | Study